Omega-3 and Sleep Agent Combination for Depression Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for depression, including antidepressants and omega-3 fatty acids, often have delayed response times and may not be effective for all patients, while sleep-inducing medications can exacerbate depression.
Innovation Solution
A pharmaceutical composition combining an omega-3 fatty acid formulation with a sleep-inducing agent, either together or in separate doses, to treat depression with a faster onset of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antidepressants are used, then depression treatment is provided, but response time is delayed (4 or more weeks)
Solution Approach 1:
The patent combines omega-3 fatty acid formulation with sleep-inducing agent to create a composite therapeutic composition. This merging of two distinct therapeutic components aims to achieve both rapid onset (from sleep induction) and sustained antidepressant effect (from omega-3 fatty acids), thereby resolving the contradiction between treatment reliability and response time.
Solution Approach 2:
The sleep-inducing agent acts preliminarily by inducing sleep first, which may facilitate subsequent therapeutic effects of omega-3 fatty acids. This preliminary action addresses the delayed response issue by creating optimal conditions for treatment effectiveness before the full antidepressant effect manifests.
2Ease of operation
If sleep-inducing medications are used to treat sleep difficulties associated with depression, then sleep problems are addressed, but depression may be exacerbated
Solution Approach 1:
The patent merges sleep-inducing agent with omega-3 fatty acid formulation in a single composition. The omega-3 fatty acids provide antidepressant effects that counterbalance the potential depressive exacerbation from sleep-inducing medications, allowing sleep treatment without compromising depression management.
Solution Approach 2:
The patent converts the potentially harmful effect of sleep-inducing medications (depression exacerbation) into a benefit by combining them with omega-3 fatty acids. The combination transforms what would be a harmful monotherapy into a synergistic treatment where the omega-3 fatty acids mitigate the adverse effects while preserving the sleep-inducing benefits.
3Reliability
If omega-3 fatty acids are used alone, then treatment is provided, but clinical trials have failed to show consistent effectiveness
Solution Approach 1:
The patent combines omega-3 fatty acid formulation with sleep-inducing agent to enhance the overall therapeutic effect. This combination may improve treatment outcome consistency by adding a second active component that works synergistically with omega-3 fatty acids, addressing the inconsistency observed in monotherapy trials.
Solution Approach 2:
The patent creates a composite pharmaceutical composition containing both omega-3 fatty acids and sleep-inducing agents. This composite approach leverages the complementary mechanisms of action of both components, potentially achieving more consistent and reliable treatment outcomes than either component alone.
Data Source
AI summary
Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. In various embodiments the pharmaceutical combinations include combinations of omega-3 fatty acids, pharmacological sleep agents, and nonpharmacological sleep therapies, and may include other ingredients such as antidepressants. The present invention relates pharmaceutical combinations and methods for their use to treat depression.